Slingshot members are tracking this event:
FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxolitinib (Jakafi) in Acute Graft-Versus-Host Disease (GVHD)
Slingshot Insights Explained
Jun 23, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Gvhd, Acute Graft-versus-host Disease, Jakafi, Ruxolitinib, Acute Graft-versus-host Disease